Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316705 | 0.89 | CYP4F2 (0.49) | CYP4F2CYP4A11SYKMAPTSIRT2 | |
| SCHEMBL30967793 | 0.87 | CYP4F2 (0.53) | CYP4F2CYP4A11SYKMAPTSIRT2 | |
| SCHEMBL2082531 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11SYKMAPTSIRT2 | |
| SCHEMBL4425984 | 0.85 | CYP4F2 (0.64) | CYP4F2CYP4A11SYKTDP1CYP4Z1 | |
| SCHEMBL13879886 | 0.82 | CYP4F2 (0.66) | CYP4F2CYP4A11SYKMAPTTDP1 | |
| SCHEMBL8616029 | 0.81 | SYK (0.50) | CYP4F2CYP4A11SYKMAPTSIRT2 | |
| SCHEMBL901671 | 0.81 | CYP4F2 (0.55) | CYP4F2CYP4A11MAPTTDP1CYP4Z1 | |
| SCHEMBL13104077 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11SYKMAPTTDP1 | |
| SCHEMBL879289 | 0.80 | CYP4F2 (0.58) | CYP4F2CYP4A11SYKTDP1CYP4Z1 | |
| SCHEMBL11064964 | 0.80 | CYP4F2 (0.46) | CYP4F2CYP4A11SYKMAPTSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20080132506-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-06-05 | — | — | US | disclosed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CYP4F2 4421/4885CYP4A11 3407/4885SYK 349/4885 |
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CYP4F2 4421/4885CYP4A11 3407/4885SYK 349/4885 |
| US-20080132506-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CYP4F2 4421/4885CYP4A11 3407/4885SYK 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.